Professional research proposal ghostwriting sites au

Professional College Essay Ghostwriting Website Au, Buy Essay. Professional scholarship editing bibliography ghostwriting sites uk custom thesis proposal ghostwriter websites Best Dissertation Proposal Ghostwriting Site Gb, Buy Essay Help Writing Professional Thesis Proposal, gb. Professional thesis ghostwriter service for mba popular movie review ghostwriting sites us Best thesis proposal ghostwriters website gb - professional professional thesis proposal ghostwriting sites gb website gb. Professional college essay ghostwriting website au Esl paper editing for hire write my zoology dissertation hypothesis world literature writer sites professional.

Localización gav- .white .offwhite .silver .black .color .client-logo-inner, .client-logo-row .white-bg .offwhite-bg .silver-bg .dark-bg .black-bg .grey-bg .color-bg, .owl-theme .owl-dots .owl-dot.active span, .owl-theme .owl-dots .owl-dot:hover span a a:hover ::selection ::-moz-selection .btn-uber-color, input[type='submit'] .btn-uber-color:hover, input[type='submit']:hover, .pagination .active a .main-nav-menu li a.current-main-nav .main-nav-menu li a.main-nav-link:focus .main-heading span, .service-icon, .service-icon-wrap .sub-nav a .sub-nav a:hover .sub-nav a:after .features-slider-trgers a .features-slider-trgers a.features-trgered .team-block h4 .mastfoot .social-nav li a .mastfoot .social-nav li a:hover #ws .price, #ws .price-specs .works-item a:hover .intro-05 h5 span, .intro-05 h1 span .intro-08 .rotator-wrap span .redirector a li:hover .tabbable-panel .font1 .font2 .font3 .font4 .font4thin .font4lht .font4bold .font4black body, p ul.slimmenu li a .sub-nav a ul.slimmenu li a .ebor-masonry .works-container .ebor-masonry .works-item .works-item:hover thumb_2 /*fixes grid tiling issue on Creative page*/ img.thumb_2 @media (max-width: 980px) .vc_single_image-wrapper img /*.client-header-title */ /*sets background to white for work example grid items*/ .works-item /*Keeps social box (blog stories) hover titles visible on touch devices that do not support hover functionality*/ @media (max-width: 980px) /*Scales social box (blog stories) navation arrows for smaller devices*/ @media (max-width: 980px) ul.slimmenu li a /* Resizes and shifts top red color bar responsively*/ @media all and (min-width: 240px) and (max-width: 1316px) @media all and (min-width: 1317px) /*hide logo since desned into header to fix responsive issue*/ .visible-lg .main-logo a /*Fixes screen shifting on mobile*/ body, html /*hides the header arrow on phone devices*/ @media all and (min-width: 240px) and (max-width: 767px) . Dissertation ghostwriter websites au professional speech editor websites for. ghostwriter service usa professional research proposal proofreading service esl.

Tilaa lehti – Pro Sail Professional speech proofreading for mba proofreading site usa. top thesis proposal ago top thesis proposal proofreading websites for mba. Tilaa Pro Sail kätevästi kotiin kannettuna. writing dissertation ghostwriter websites au professional speech editor websites for masters best. research paper ghostwriter service usa professional research proposal proofreading service esl.

Professional Thesis Proposal Ghostwriting Sites Gb - hrmin Nadat ik in de afgelopen twee jaar de boeken Kickstart Word Press en de Essentie van Joomla heb mogen schrijven en uitbrengen, is het nu tijd voor een wat groter project. Professional thesis proposal ghostwriting sites gb. proposal Professional Research Proposal Ghostwriting For. sites au for mba professional.

Best School Essay Editor Site Uk, Buy Essay Online - I have used quite a few essay writing services, but this site is absolutely the best so far! Their writer accurately followed all my initial instructions and implemented minor changes to the first draft very quickly. I managed to place my order very quickly and their support representative assisted my in every possible way. However, the final paper wasn’t as good as I expected so I asked for the revision. They accepted all my revision instructions and I received the revised paper within 8 hours or so. A quick look showed that this time the paper was polished well enough so I could turn it in immediately without revising it myself. Students worldwide get absolutely sad seeing as dissertation deadline approaches. In a desperate attempt of getting academic assistance they start asking: “can someone write me an essay? No need to nervous, blaming your professor – just pass tasks to us. Our hired writers will take care of them within hours. We give our customers unique approach offered by no other service when they ask to write me an essay. We have successfully assisted hundreds of students worldwide and try to keep it that way. We work with many native English speaking writers from US, UK, Canada and Australia that have degrees in different academic fields. We value our reputation – numerous positive reviews around the internet and word of mouth proves it. We provide the hhest level of customer-writer communication to achieve astonishing results. Upon delivery, we provide free unlimited revisions and corrections to make your order suit the initial requirements. We aim on supplying students with qualified and genuine support to help receive new academic hehts. The possibility of getting a much needed advice from someone willing to write my college essay for me is appealing. Some of you mht feel insecure due to different accompanying issues: quality, ethics. We want to reassure you that those worries are groundless. Our superb team of qualified writers work days and nht to help you to write my school essays. An absolute logical thing would be to take a good closer look at our previous work shown in the “examples” section. We have successfully delivered tens of thousands of papers on any possible topic. It gives strong confidence that we can exceed expectations while you place an order with us. It’s been easy and fast to find someone and pay to do essay on a weekly bases. Those people were begging: “help me write my essay please” they said. It’s an easy way to tell anyone who’s asked themselves “who can write my essay cheap? Ask to help me write my college essay for me and after you proceed with the payment our writer is going to start working rht away! Don’t hesitate – place your order, saying write essays for me! Responsive customer support that can guide to write an essay for me on any topic and level of difficulty. Every time you visit our web site and ask to write my business essays, we are more than happy to help you with that and assist during the whole process. Our support will carefully consider your requests, accurately answer questions. We are ready to communicate concerning your order using email, telephone or live chat, to help write an essay for me. We are constantly improving their experience by requesting feedbacks and implementing their suggestions! What is distinctly different about our life saving hand writing service features is: you place an order and always get perfect results! We provide a well-researched, orinal paper without plagiarism, written, proofread and edited to your requirements by an available native English language speaking writer matching to the job and has a degree in a required field. Our huge experience on dealing with complicated papers allows us to guarantee in-time delivery along with excellent grade each time students buy argumentative assnments with title. Write My Essay4can assist you with problems in your academic career. One has every reason to ask a writer to write my paper and earn a teacher’s approval in return! We are already the key to your academic successes, a tool that unlocks the door to a world of new opportunities and stunning perspectives. Vital questions arise while students start looking for someone to write my essay for me cheap. It is impossible to accuse a person of contacting a standard academic writing help service project simply due to lack of evidences. We guarantee superb quality of orders that is far beyond anything that one has experienced before. We urge not to worry about the legal issues one can face immediately during the process of cooperation with us. There no terms or law rules that university can really refer to that prohibit the use of services like our own. Students are free to have an idea of anyone to write me an essay online! We understand that today academic help plays a crucial part in the whole days of studying. To get a rated comprehensive support to write essay online on any subject, we suggest that you upload a sample essay and instructions that you have previously submitted. This template will be of a great use for a writer assned to the case. It is going to allow to create a perfect paper that corresponds to your needs. Once you decided to look for a service that is able to write essay for money, you should upload the necessary information and fill in the order form. The next step is to communicate with the assned writer directly to achieve first course results. That’s the major thing many students are afraid of when search in google something like: “help me write an essay for me”. We want to assure you that every single of our papers is double-checked. We use a state-of-the-art plagiarism check software to exclude even the tiniest possibility of plagiarism. Even more, while you look for someone to write my essay, orinal, well researched and formatted papers is what you get! When your task is about writing a research paper or any other academic paper, there is nothing worse than coming up with the title for your masterpiece. Some of you may think it is an easy task to get the title for your research paper, but you should not be too optimistic in this case. Read more “Tommy made fun of me, so I nicked his eye with a stick.” – It’s a typical example of diction – one of the literary terms, which refers to a writer’s choice of word. Writing an essay is always about choosing the correct words. Perhaps, immersion is the most effective way to learn a se... Let them see.” In terms of academic writing, this phrase means being able to draw visual images with the help of words. Read more Henry David Thoreau once said, “If you would convince a man that he does wrong, do rht. Top school ghostwriter websites au themes of a tale of two cities cheap. Custom thesis proposal ghostwriters service for university professional blog. for school definition on physics best case study ghostwriters service uk.

Cheap Research Proposal Writers Sites Usa Battisti, Ph D; Elizabeth Wager, Ph D; Lise Baltzer; Dan Bridges, Ph D; Angela Cairns; Christopher I. From Janssen Research & Development, Raritan, New Jersey; Sideview, Princes Risborough, United Kingdom; Novo isk, Bagsværd, Denmark; Nucleus Global, London, United Kingdom; Ashfield Healthcare Communications, Macclesfield, United Kingdom; Pharmaco Economics, Springer International Publishing, Cham, Switzerland; New York Medical College, Valhalla, New York; Med Immune, Gaithersburg, Maryland; Pfizer, New York, New York; Medtronic, Mounds View, Minnesota; Bristol-Myers Squibb, Philadelphia, Pennsylvania; Baxalta, Deerfield, Illinois; Keithveitch Communications, Amsterdam, The Netherlands; Pro Scribe (Envision Pharma ), Sydney, Australia; and Medicite, Yardley, Pennsylvania. From Janssen Research & Development, Raritan, New Jersey; Sideview, Princes Risborough, United Kingdom; Novo isk, Bagsværd, Denmark; Nucleus Global, London, United Kingdom; Ashfield Healthcare Communications, Macclesfield, United Kingdom; Pharmaco Economics, Springer International Publishing, Cham, Switzerland; New York Medical College, Valhalla, New York; Med Immune, Gaithersburg, Maryland; Pfizer, New York, New York; Medtronic, Mounds View, Minnesota; Bristol-Myers Squibb, Philadelphia, Pennsylvania; Baxalta, Deerfield, Illinois; Keithveitch Communications, Amsterdam, The Netherlands; Pro Scribe (Envision Pharma ), Sydney, Australia; and Medicite, Yardley, Pennsylvania. From Janssen Research & Development, Raritan, New Jersey; Sideview, Princes Risborough, United Kingdom; Novo isk, Bagsværd, Denmark; Nucleus Global, London, United Kingdom; Ashfield Healthcare Communications, Macclesfield, United Kingdom; Pharmaco Economics, Springer International Publishing, Cham, Switzerland; New York Medical College, Valhalla, New York; Med Immune, Gaithersburg, Maryland; Pfizer, New York, New York; Medtronic, Mounds View, Minnesota; Bristol-Myers Squibb, Philadelphia, Pennsylvania; Baxalta, Deerfield, Illinois; Keithveitch Communications, Amsterdam, The Netherlands; Pro Scribe (Envision Pharma ), Sydney, Australia; and Medicite, Yardley, Pennsylvania. From Janssen Research & Development, Raritan, New Jersey; Sideview, Princes Risborough, United Kingdom; Novo isk, Bagsværd, Denmark; Nucleus Global, London, United Kingdom; Ashfield Healthcare Communications, Macclesfield, United Kingdom; Pharmaco Economics, Springer International Publishing, Cham, Switzerland; New York Medical College, Valhalla, New York; Med Immune, Gaithersburg, Maryland; Pfizer, New York, New York; Medtronic, Mounds View, Minnesota; Bristol-Myers Squibb, Philadelphia, Pennsylvania; Baxalta, Deerfield, Illinois; Keithveitch Communications, Amsterdam, The Netherlands; Pro Scribe (Envision Pharma ), Sydney, Australia; and Medicite, Yardley, Pennsylvania. From Janssen Research & Development, Raritan, New Jersey; Sideview, Princes Risborough, United Kingdom; Novo isk, Bagsværd, Denmark; Nucleus Global, London, United Kingdom; Ashfield Healthcare Communications, Macclesfield, United Kingdom; Pharmaco Economics, Springer International Publishing, Cham, Switzerland; New York Medical College, Valhalla, New York; Med Immune, Gaithersburg, Maryland; Pfizer, New York, New York; Medtronic, Mounds View, Minnesota; Bristol-Myers Squibb, Philadelphia, Pennsylvania; Baxalta, Deerfield, Illinois; Keithveitch Communications, Amsterdam, The Netherlands; Pro Scribe (Envision Pharma ), Sydney, Australia; and Medicite, Yardley, Pennsylvania. Yarker, Ph D From Janssen Research & Development, Raritan, New Jersey; Sideview, Princes Risborough, United Kingdom; Novo isk, Bagsværd, Denmark; Nucleus Global, London, United Kingdom; Ashfield Healthcare Communications, Macclesfield, United Kingdom; Pharmaco Economics, Springer International Publishing, Cham, Switzerland; New York Medical College, Valhalla, New York; Med Immune, Gaithersburg, Maryland; Pfizer, New York, New York; Medtronic, Mounds View, Minnesota; Bristol-Myers Squibb, Philadelphia, Pennsylvania; Baxalta, Deerfield, Illinois; Keithveitch Communications, Amsterdam, The Netherlands; Pro Scribe (Envision Pharma ), Sydney, Australia; and Medicite, Yardley, Pennsylvania. From Janssen Research & Development, Raritan, New Jersey; Sideview, Princes Risborough, United Kingdom; Novo isk, Bagsværd, Denmark; Nucleus Global, London, United Kingdom; Ashfield Healthcare Communications, Macclesfield, United Kingdom; Pharmaco Economics, Springer International Publishing, Cham, Switzerland; New York Medical College, Valhalla, New York; Med Immune, Gaithersburg, Maryland; Pfizer, New York, New York; Medtronic, Mounds View, Minnesota; Bristol-Myers Squibb, Philadelphia, Pennsylvania; Baxalta, Deerfield, Illinois; Keithveitch Communications, Amsterdam, The Netherlands; Pro Scribe (Envision Pharma ), Sydney, Australia; and Medicite, Yardley, Pennsylvania. From Janssen Research & Development, Raritan, New Jersey; Sideview, Princes Risborough, United Kingdom; Novo isk, Bagsværd, Denmark; Nucleus Global, London, United Kingdom; Ashfield Healthcare Communications, Macclesfield, United Kingdom; Pharmaco Economics, Springer International Publishing, Cham, Switzerland; New York Medical College, Valhalla, New York; Med Immune, Gaithersburg, Maryland; Pfizer, New York, New York; Medtronic, Mounds View, Minnesota; Bristol-Myers Squibb, Philadelphia, Pennsylvania; Baxalta, Deerfield, Illinois; Keithveitch Communications, Amsterdam, The Netherlands; Pro Scribe (Envision Pharma ), Sydney, Australia; and Medicite, Yardley, Pennsylvania. From Janssen Research & Development, Raritan, New Jersey; Sideview, Princes Risborough, United Kingdom; Novo isk, Bagsværd, Denmark; Nucleus Global, London, United Kingdom; Ashfield Healthcare Communications, Macclesfield, United Kingdom; Pharmaco Economics, Springer International Publishing, Cham, Switzerland; New York Medical College, Valhalla, New York; Med Immune, Gaithersburg, Maryland; Pfizer, New York, New York; Medtronic, Mounds View, Minnesota; Bristol-Myers Squibb, Philadelphia, Pennsylvania; Baxalta, Deerfield, Illinois; Keithveitch Communications, Amsterdam, The Netherlands; Pro Scribe (Envision Pharma ), Sydney, Australia; and Medicite, Yardley, Pennsylvania. From Janssen Research & Development, Raritan, New Jersey; Sideview, Princes Risborough, United Kingdom; Novo isk, Bagsværd, Denmark; Nucleus Global, London, United Kingdom; Ashfield Healthcare Communications, Macclesfield, United Kingdom; Pharmaco Economics, Springer International Publishing, Cham, Switzerland; New York Medical College, Valhalla, New York; Med Immune, Gaithersburg, Maryland; Pfizer, New York, New York; Medtronic, Mounds View, Minnesota; Bristol-Myers Squibb, Philadelphia, Pennsylvania; Baxalta, Deerfield, Illinois; Keithveitch Communications, Amsterdam, The Netherlands; Pro Scribe (Envision Pharma ), Sydney, Australia; and Medicite, Yardley, Pennsylvania. From Janssen Research & Development, Raritan, New Jersey; Sideview, Princes Risborough, United Kingdom; Novo isk, Bagsværd, Denmark; Nucleus Global, London, United Kingdom; Ashfield Healthcare Communications, Macclesfield, United Kingdom; Pharmaco Economics, Springer International Publishing, Cham, Switzerland; New York Medical College, Valhalla, New York; Med Immune, Gaithersburg, Maryland; Pfizer, New York, New York; Medtronic, Mounds View, Minnesota; Bristol-Myers Squibb, Philadelphia, Pennsylvania; Baxalta, Deerfield, Illinois; Keithveitch Communications, Amsterdam, The Netherlands; Pro Scribe (Envision Pharma ), Sydney, Australia; and Medicite, Yardley, Pennsylvania. From Janssen Research & Development, Raritan, New Jersey; Sideview, Princes Risborough, United Kingdom; Novo isk, Bagsværd, Denmark; Nucleus Global, London, United Kingdom; Ashfield Healthcare Communications, Macclesfield, United Kingdom; Pharmaco Economics, Springer International Publishing, Cham, Switzerland; New York Medical College, Valhalla, New York; Med Immune, Gaithersburg, Maryland; Pfizer, New York, New York; Medtronic, Mounds View, Minnesota; Bristol-Myers Squibb, Philadelphia, Pennsylvania; Baxalta, Deerfield, Illinois; Keithveitch Communications, Amsterdam, The Netherlands; Pro Scribe (Envision Pharma ), Sydney, Australia; and Medicite, Yardley, Pennsylvania. From Janssen Research & Development, Raritan, New Jersey; Sideview, Princes Risborough, United Kingdom; Novo isk, Bagsværd, Denmark; Nucleus Global, London, United Kingdom; Ashfield Healthcare Communications, Macclesfield, United Kingdom; Pharmaco Economics, Springer International Publishing, Cham, Switzerland; New York Medical College, Valhalla, New York; Med Immune, Gaithersburg, Maryland; Pfizer, New York, New York; Medtronic, Mounds View, Minnesota; Bristol-Myers Squibb, Philadelphia, Pennsylvania; Baxalta, Deerfield, Illinois; Keithveitch Communications, Amsterdam, The Netherlands; Pro Scribe (Envision Pharma ), Sydney, Australia; and Medicite, Yardley, Pennsylvania. From Janssen Research & Development, Raritan, New Jersey; Sideview, Princes Risborough, United Kingdom; Novo isk, Bagsværd, Denmark; Nucleus Global, London, United Kingdom; Ashfield Healthcare Communications, Macclesfield, United Kingdom; Pharmaco Economics, Springer International Publishing, Cham, Switzerland; New York Medical College, Valhalla, New York; Med Immune, Gaithersburg, Maryland; Pfizer, New York, New York; Medtronic, Mounds View, Minnesota; Bristol-Myers Squibb, Philadelphia, Pennsylvania; Baxalta, Deerfield, Illinois; Keithveitch Communications, Amsterdam, The Netherlands; Pro Scribe (Envision Pharma ), Sydney, Australia; and Medicite, Yardley, Pennsylvania. From Janssen Research & Development, Raritan, New Jersey; Sideview, Princes Risborough, United Kingdom; Novo isk, Bagsværd, Denmark; Nucleus Global, London, United Kingdom; Ashfield Healthcare Communications, Macclesfield, United Kingdom; Pharmaco Economics, Springer International Publishing, Cham, Switzerland; New York Medical College, Valhalla, New York; Med Immune, Gaithersburg, Maryland; Pfizer, New York, New York; Medtronic, Mounds View, Minnesota; Bristol-Myers Squibb, Philadelphia, Pennsylvania; Baxalta, Deerfield, Illinois; Keithveitch Communications, Amsterdam, The Netherlands; Pro Scribe (Envision Pharma ), Sydney, Australia; and Medicite, Yardley, Pennsylvania. This updated Good Publication Practice (GPP) guideline, known as GPP3, builds on earlier versions and provides recommendations for individuals and organizations that contribute to the publication of research results sponsored or supported by pharmaceutical, medical device, diagnostics, and biotechnology companies. The recommendations are desned to help individuals and organizations maintain ethical and transparent publication practices and comply with legal and regulatory requirements. These recommendations cover publications in peer-reviewed journals and presentations (oral or poster) at scientific congresses. The International Society for Medical Publication Professionals invited more than 3000 professionals worldwide to apply for a position on the steering committee, or as a reviewer, for this guideline. The GPP2 authors reviewed all applications ( = 241) and assembled an 18-member steering committee that represented 7 countries and a diversity of publication professions and institutions. From the 174 selected reviewers, 94 sent comments on the second draft, which steering committee members incorporated after discussion and consensus. The resulting guideline includes new sections (Principles of Good Publication Practice for Company-Sponsored Medical Research, Data Sharing, Studies That Should Be Published, and Plagiarism), expands guidance on the International Committee of Medical Journal Editors' authorship criteria and common authorship issues, improves clarity on appropriate author payment and reimbursement, and expands information on the role of medical writers. By following good publication practices (including GPP3), individuals and organizations will show integrity; accountability; and responsibility for accurate, complete, and transparent reporting in their publications and presentations. Incomplete, inaccurate, misleading, or delayed reporting of medical research may result in poorly informed decision making and reduce the efficiency and quality of health care (1). Therefore, scientific and clinical research should be reported in a complete, accurate, balanced, and timely manner. Such research is often initiated by, or involves collaboration with, commercial organizations, such as pharmaceutical, biotechnology, medical device, and diagnostics companies. This updated Good Publication Practice guideline, known as GPP3, is desned primarily to help individuals and organizations maintain ethical practices when they contribute to the communication of this type of research. The principles of GPP3 apply to all research, however, so we expect that this guideline will be applicable to all medical and health care professionals involved in publications. The GPP guideline, published in 2003 (2) and updated in 2009 (as GPP2) (3), has been widely adopted. In an international survey of almost 500 people involved in publishing industry-sponsored research, more than 90% of respondents said they routinely referred to GPP2, which is a similar proportion to those who reported using International Committee of Medical Journal Editors (ICMJE) guidelines (4). The GPP guidelines have also been endorsed by medical journals (5) and cited in their instructions to authors. The latest revision, GPP3, reflects changes in the medical publications environment and aims to clarify and strengthen the principles and practices described in earlier versions. This guideline also reflects some important changes from GPP2 (Table). Throughout the guideline, we use the term "publications" to include the full range of formats published in peer-reviewed journals (for example, orinal research articles, short reports, reviews, or letters to the editor) and "presentations" to include abstracts, posters, and slides for oral presentations at scientific congresses. "Sponsors" are organizations that provide primary support, which may include funding, for a study. "Publication professionals" are professional medical writers, publication planners, and publication managers, usually working either in or for companies. This guideline does not cover regulatory documents, medical education programs, or marketing or advertising materials, all of which are regulated or accredited by specific national or regional authorities. = 288); and a distribution list from the Medical Publishing Inshts and Practices initiative that included approximately 1400 investators, researchers, and journal editors. Candidates were invited to volunteer as members of the GPP3 steering committee or reviewers (or both). Eht GPP2 authors screened the applications ( = 241). Of 118 steering committee applicants, 11 were chosen and joined 7 of the former GPP2 authors to provide a broad range of perspectives (from 7 countries, including employees of pharmaceutical, biotechnology, medical device, and medical communication companies; freelance writers; journal editors; and publishers). From that first round of invitations, 153 applicants agreed to participate as reviewers. Personal invitations from steering committee members added 21 editors and academics to the reviewer list (Fure). The steering committee used a repeated survey process to reach consensus on the scope, title, and format for the new version. After agreement on the outline, subcommittees updated or developed specific sections. The draft GPP3 guideline was circulated to the reviewer panel after a first full draft was developed, edited, reviewed, and approved by the steering committee (Fure). The 94 sets of responses, comprising more than 2100 comments, were anonymized, collated, assessed, and ranked by steering committee members based on the frequency of comments received on a particular section, whether reviewers had marked the comment as critical (that is, a substantive disagreement) or beneficial (that is, a clarification or suggestion), and the steering committee members' interpretation of the importance of the comment. The list of ranked comments was then reviewed and discussed by the steering committee. Subcommittees for each section also evaluated all comments relating to their section and revised that section accordingly. The development of the GPP3 guideline was initiated and sponsored by ISMPP. The sponsor provided the resources to help assemble the GPP3 steering committee by providing administrative assistance, granting access to the mailing list of ISMPP members, sending out e-mails to members and potential reviewers, managing the database of respondents, setting up the reviewer Web site, and updating the GPP Web site. Several of the steering committee members are also members of the ISMPP Board of Trustees. However, they acted as individuals, and not on behalf of ISMPP, in contributing to GPP3. The ISMPP staff did not direct or control the content of this guideline.2. Reporting and publication processes should follow applicable laws (for example, Food and Drug Administration Amendments Act of 2007) and guidelines (for example, ICMJE recommendations and reporting guidelines found on the Enhancing the QUAlity and Transparency Of health Research [EQUATOR] Network).4. Publication planning and development should be a collaboration among all persons involved (for example, clinicians, statisticians, researchers, and publication professionals, including medical writers) and reflect the collaborative nature of research and the range of ss required to conduct, analyze, interpret, and report research findings.5. The rhts, roles, requirements, and responsibilities of all contributors (that is, authors and any nonauthor contributors) should be confirmed in writing, ideally at the start of the research and, in all cases, before publication preparation begins.7. The authors should take responsibility for the way in which research findings are presented and published, be fully involved at all stages of publication and presentation development, and be willing to take public responsibility for all aspects of the work.8. Author lists and contributorship statements should accurately reflect all substantial intellectual contributions to the research, data analyses, and publication or presentation development. Relevant contributions from persons who did not qualify as authors should also be disclosed.9. The role of the sponsor in the desn, execution, analysis, reporting, and funding (if applicable) of the research should be fully disclosed in all publications and presentations of the findings. Any involvement by persons or organizations with an interest (financial or nonfinancial) in the findings should also be disclosed. We hope that GPP3 will complement the many useful guidelines and recommendations that are available (for example, those from the American Medical Writers Association, Council of Science Editors, Committee on Publication Ethics, European Association of Science Editors, European Medical Writers Association, ICMJE, International Federation of Pharmaceutical Manufacturers & Associations, ISMPP, Medical Publishing Inshts and Practices, and World Association of Medical Editors) and encourage adherence to and further research on responsible publication practices. We recognize that, to be effective, guidelines must be evidence-based, well-understood, and widely followed. This requires active research, promotion, education, and monitoring. Awareness and knowledge of publication guidelines are generally hh among publication professionals, especially those working in biopharmaceutical and medical communication companies and those who belong to organizations, such as ISMPP, American Medical Writers Association, and European Medical Writers Association (4). However, work is needed to ensure that good practice is followed in all sectors and all world regions. We encourage journals, congresses, and academic institutions to endorse GPP3 and help disseminate it throughout the research community. Publication plans help research sponsors ensure that findings are published and presented in a responsible, ethical, complete, and timely manner. Plans also establish timelines and necessary resources (6). However, authors must retain responsibility for decisions about the content and timing of individual publications and presentations. The sponsor should develop publication plans internally using a cross-functional publications team that may include clinicians, statisticians, preclinical and translational scientists, health outcomes specialists, medical affairs representatives, and publication professionals. Commercial functions should neither direct publication planning or development nor be involved in publication review or approval (4, 7). A publication steering committee may be formed to plan and oversee the development of publications and presentations from a study or of studies. The publication steering committee is initiated by the sponsor, usually by a person with responsibility for the study (for example, the clinical study lead) or a publication professional, who in consultation with a multidisciplinary of colleagues (for example, clinicians and statisticians) selects the steering committee chair and members. The publication steering committee may be a sub of the trial steering committee, which is responsible for the desn and execution of the study. As with any committee, the publication steering committee will work more efficiently if the number of participants is limited. The committee's composition may change over time and include study investators, employees of the sponsor (for example, scientists, clinicians, or statisticians), contractors involved in the study, persons with expertise in the therapeutic area, or publication professionals (for example, publication planners, managers, or medical writers). Members of the publication steering committee may become authors (section 2.3) if they meet all ICMJE (or journal-specific) authorship criteria, but committee membership does not automatiy confer authorship. We recommend that• a charter or guidance document describing the roles and responsibilities of the publication steering committee is developed, especially if the research involves international and multi-institution collaboration; We also recommend that an authorship working is formed by members of the publication steering committee to ensure appropriate and transparent authorship decisions, which is described in the recent Medical Publishing Inshts and Practices authorship framework initiative (8). Findings from all clinical trials (including noninterventional studies involving human participants) should be made public, ideally by publication in a peer-reviewed journal. Research results should be submitted for publication in a peer-reviewed journal regardless of whether the findings are positive, negative, or inconclusive or whether the studied intervention is investational, is licensed, or has been discontinued or withdrawn from the market (9–11). In such situations (for example, when the data are of limited scientific or clinical value or in the case of multiple journal rejections), posting results on a public Web site, trial registry site (for example, Clinical or the European Clinical Trials Database [Eudra CT]), or data repository may be an option for disclosure. For licensed products, manuscripts should ideally be submitted within 12 months (or 18 months at the latest) of study completion, allowing for congress presentation first (if required). For investational products, manuscripts should be submitted within 12 months (or 18 months at the latest) of product approval or within 18 months of product discontinuation (10). The primary publication or publications should clearly, accurately, and comprehensively describe the methods and results for the primary study outcome or outcomes, as defined in the protocol, and safety data. Secondary outcomes, exploratory analyses, and post hoc analyses should be clearly identified as such; these may be included in the primary publication or published separately, in which case they should clearly reference the primary publication and should not be published before it. Public posting of summaries of clinical trial results on trial registries (for example, Clinical or Eudra CT) does not constitute prior publication and does not preclude the ethical oblation to attempt to publish the complete methods and findings (7). Likewise, presentation of results at congresses does not constitute or substitute full publication in a peer-reviewed journal. Embargoes set by journals, congresses, or other media must be respected. For example, authors, sponsors, and institutions should not issue a press release about an article that has been accepted for publication without consulting the journal.• the publication is clearly presented as an analysis derived from the primary publication results or marked as a translation, with appropriate permission obtained from the previous publisher and copyrht laws upheld. Reuse of material from the authors' previous publications ("self-plagiarism" or "text recycling") should generally be avoided; however, exceptions may include descriptions of study methods or data sources (for example, mortality statistics or safety registries). Note that copyrht of published or presented content may be held by the publisher, so authors may need permission to reuse their own work. Plagiarism, the practice of taking or closely imitating the work of others without their authorization and representing it as one's own, is unethical and unacceptable (12–14). Care should be taken to ensure that any publication or presentation is orinal and that any copied or republished material is clearly identified as such, appropriate copyrht permission is obtained, and the orinal author or authors and copyrht holder are appropriately acknowledged (15, 16). National and international guidelines, including the Declaration of Helsinki (9), require clinical trials to be registered on public Web sites (for example, Clinical or Eudra CT) before participants are enrolled. Some legislation also requires a summary of key findings of certain trials to be posted on the same Web site within a specified period after study completion. Many journals have made trial registration a prerequisite for publication (7). Clinical trial registration or identifier numbers should be included in all presentations and publications, including abstracts, that present findings from a registered study or studies so that the source may be identified, even if this is not required by the journal or congress. Unregistered clinical trials should be declared as such, and the reason for nonregistration should be provided. Companies should have policies and procedures in place to document the complete process of publication and presentation development and ensure maintenance of shareable data that could be requested after publication (17). All nonsponsor-affiliated authors should be informed of such processes and the types of documents that will be retained. Sponsors have a duty to ensure ethical practices are applied across all of the publications and presentations that they support. Companies should describe these oblations, and those of authors, in a written agreement with authors before work on a publication begins. The written agreement is generally not a legal document, but its receipt should be acknowledged by the authors.• disclose relevant financial and nonfinancial relationships in all publications and presentations, including potential competing interests, all sources of funding, and other types of support for the study;• provide authors with access to all of the study information necessary to prepare the publication or presentation (for example, the protocol, statistical analysis plan, and study report) before writing begins, allow relevant access to anonymized patient-level data, and provide reasonable additional analyses in support of the publication on request;• advise the authors of the sponsors' financial reporting requirements (if any) to comply with transparency laws and regulations, if this is relevant to editorial or other support provided by the sponsors; and The agreement should also commit the authors to take responsibility for the content, accuracy, and completeness of the publication or presentation; work together to agree to the order in which authors will be listed (for example, in descending order of contribution to the research and publication or alphabetiy after the primary author); and inform the sponsors of relevant publication policies from the authors' institutions. The agreement should state that the authors are responsible for all final decisions on publication content, for final approval of the versions for submission, and of the version for publication or presentation. It should confirm the authors' freedom to publish the study results without hindrance from the sponsors and respect the sponsors' rht to review drafts in a timely manner to ensure accuracy, adherence to any regulatory requirements, and protection of their intellectual property. It should also respect the institutional policies of authors, investators, and other contributors and policies of the sponsors. We recommend that authors should not enter into agreements that do not uphold these principles. Sponsors must provide authors and other contributors with full access to relevant aggregated study data (ensuring patient anonymity is maintained) before work on a publication or presentation begins (11, 18) and any missing or final data as soon as they become available. These data should include all prespecified primary and secondary outcomes and ancillary information necessary to accurately and correctly appraise the quality and robustness of the findings (for example, study protocol, statistical analysis plan, statistical report, validated data tables, and clinical study report) and reasonable additional analyses requested by the authors. Patient confidentiality must be respected, and identifiable individual-level information should be anonymized or removed where necessary. We recommend using the ICMJE authorship criteria, updated in 2013, unless the target journal or congress has different requirements (Appendix Table 1) (7). To qualify, authors must meet all 4 ICMJE criteria listed in Appendix Table 1; they should be able to identify which of their coauthors are responsible for specific parts of the work and have confidence in the integrity of their contributions. The ICMJE also recommends that persons who meet the first criterion (Appendix Table 1) should be given the opportunity to meet the other authorship criteria. It is recognized, however, that many may be involved in the desn and execution of clinical trials; in our opinion, it is not feasible to offer the opportunity of authorship to all of them. Priority should be given to the key contributors who have the necessary background to analyze or interpret the findings (20). Authorship criteria should be applied consistently. All authors listed on a publication or presentation must fulfill the authorship criteria (that is, there should be no guest authors), and all persons who fulfill the criteria must be listed as authors, including company- or sponsor-employed authors and contractors (that is, there should be no ghost authors). Before writing begins, the author should identify a lead author who will direct the content development and a corresponding author who will be responsible for communicating with the journal or congress (these may, but do not have to be, the same person) (11). Appendix Table 2 lists some of the common issues about authorship and provides some guidance. Authorship must not be used as a reward or gift for services rendered. For example, trial enrollment or cal assistance (for example, laboratory assistance, data acquisition, statistical programming, clinical trial management, or editing services) are not themselves criteria for authorship. Likewise, acquisition of funding or supervision of a research or department is insufficient to qualify someone as an author. Authorship must represent not only a substantial intellectual contribution to both the research being reported and the development of the publication (or presentation) but also a willingness and ability to take public responsibility for these (Appendix Table 1). Companies may reimburse reasonable publication- or presentation-related out-of-pocket expenses (for example, travel and accommodation) incurred by authors and other contributors and pay for publication activities (for example, statistical analysis, medical writing, editing, or similar services) to assist authors in the development of publications and presentations. Any such payments should reflect the services provided and be at fair market value. Details of any payments (or other forms of compensation) to authors and contributors must be fully disclosed and comply with applicable regulations and company, institutional, journal, and congress policies. Payment should never be made (or offered) simply to attract someone to be an author or influence an author's opinion. As it is difficult to prove specific intent, sponsors may choose to adopt policies that prohibit compensation for time spent authoring a publication or presentation. Payments should not be made to authors who are employed by an institution or organization that is already in receipt of funding to undertake and publish the research. Professional medical writers may assist authors in preparing publications and presentations. Properly trained and experienced writers can help authors with the development of publications in a compliant, complete, and timely manner, particularly when authors have limited time or knowledge of publication ethics and current publication and reporting guidelines (7, 21–23). In addition to cal expertise, medical writers should have a good understanding of publication ethics and current publication guidelines. Training programs are provided by various organizations (for example, ISMPP, American Medical Writers Association, European Medical Writers Association, and Drug Information Association), and certification programs with enforceable codes of conduct have been introduced (ISMPP certification Web site, American Medical Writers Association certification Web site, org/certification). Professional medical writers have a responsibility to ensure that findings are presented clearly, accurately, and without any intent of misleading readers (21, 24, 25). Emerging evidence suggests that the use of professional medical writers may enhance publication quality and has been associated with a reduced risk for retractions due to misconduct (26, 27). Properly acknowledged professional medical writers are not ghostwriters (24, 28, 29). Professional medical writers should strive to ensure that authors disclose the writer's involvement and funding source and that all contributors follow good publication practices (4). The contributions of professional medical writers, their funding sources, and any other potential competing interests must be disclosed (as with all other nonauthor contributors [section 2.5]). We encourage journal editors to ask authors to complete a checklist (30) to ensure that ethical guidelines have been followed and any writing or editorial assistance is appropriately acknowledged (section 2.5).• The authors will control and direct the content of the publication or presentation. The writer must receive direction from the authors at the earliest possible stage (for example, before the outline is prepared). During the development of the manuscript or presentation, the writer should be in frequent contact with the authors and ensure that the authors' contributions are documented. The writer should work with the sponsor and elible authors to ensure that all listed authors meet applicable authorship criteria (for example, as described by the ICMJE). If needed, translation services should be provided to authors to ensure they can provide detailed feedback and contribute fully. With the corresponding author's permission, and if allowed by the journal or congress, a medical writer (or an appropriately supervised delegate) may complete the administrative tasks associated with submitting the publication to the journal or presentation to the congress. Medical writers generally do not meet accepted authorship criteria, but there may be exceptions (for example, if they contribute substantially to a review article). If writers qualify for authorship (that is, meet ICMJE or journal-specific criteria), they should be listed as authors and their financial relationship with the sponsor should be disclosed. We support the use of a contributorship model to describe each person's role in the development of a publication or presentation because this should reduce ambuity about contributions to the work (7). Clear and concise descriptions of the role of each author and any listed nonauthor contributors (for example, statisticians, medical writers, and research personnel) should be included within the publication or presentation. All specific journal or congress requirements for acknowledgment and disclosure should be followed. Each person named in the acknowledgment section should review the wording describing his or her contribution and provide written permission to be included. Nonauthor contributors listed in the acknowledgment section should not be expected to approve the final manuscript or presentation, but a courtesy copy may be provided before submission. The role (if any) of the sponsor (for example, funding of the study, its publication, or writing support; involvement in the desn of the study or the collection, analysis, or interpretation of the data; or review of the manuscript) should always be clearly disclosed (7).• Author contributions; for example, "Authors A and B desned the study. Authors A and C analyzed and interpreted the study data. All authors critiy reviewed the manuscript and approved the final version for submission."• Contributions to the publication or presentation and the affiliations of any nonauthor contributors; for example, "Under the direction of the authors, Writer D (ST Medical Writing) drafted the initial version of the manuscript, and Company U provided overall trial management, performed the statistical analyses and verified the accuracy of the data presented. The sponsor (Company V) was responsible for study desn, and provided a formal review of the publication, but the authors had final authority, including choice of journal."• Sponsorship and funding sources, such as sponsorship of the study; provision of funding for an independent study; any payments to the authors; and funding of professional medical writing support, statistical analyses, or other professional services. For example, "The study was sponsored by XY Pharmaceuticals, the manufacturer of drug Z. All authors received travel expenses from XY Pharmaceuticals to meet and plan the preparation of the manuscript. Medical writing services provided by Writer D from ST Medical Writing were funded by XY Pharmaceuticals."• Names of persons who did not contribute to the manuscript or presentation development but who deserve to be acknowledged for their contribution to the study, such as study investators, persons who provided important cal expertise, or the participants (as a ). When journals or congresses do not allow inclusion of this information within the publication or presentation, we recommend that it is included with the submission (if possible; for example, in a cover letter or supplementary file). At a minimum, this information should be documented in the project file. When discussing relevant relationships authors may have with commercial (or noncommercial) entities, the term "disclosures" may be preferable to "conflicts of interest" or "competing interests" because these latter terms may imply actual (rather than perceived or potential) conflicts and may inadvertently prevent full disclosure if the authors interpret them narrowly or fail to consider other relationships that may affect the manuscript. Authors should disclose financial and nonfinancial relationships that could be perceived to bias their work or influence professional judgment. In general, this means disclosing the names of, and relationship with, all pharmaceutical, biologics, medical device, and diagnostics manufacturers in which an author (or close family member) is employed, is a contractor, provides services, or has otherwise collaborated in commercial or scientific pursuits—even in the absence of direct monetary remuneration. The stock holdings and issued or pending patents of an author or family member may also be relevant. Any institutional, company, and journal disclosure requirements should also be followed. If no time frame for disclosure is specified, we recommend following the ICMJE disclosure form and using a 36-month disclosure window. Disclosure statements should be provided (on submission) for each author of a publication (31) or congress abstract (if space requirements allow). Disclosure statements should also be included in slides for oral presentations and on posters. For the purpose of this guideline, we define a primary publication as the first full report in a peer-reviewed journal of the primary outcomes of a study and secondary publications as additional reports of secondary or exploratory objectives, sub analyses, or post hoc analyses. Primary publications should be published before any secondary publications. The primary publication or first presentation of any type of study should indicate this fact (to distinguish it from any subsequent secondary publications or presentations) and should include the clinical trial identifier. Secondary publications should always reference the primary publication, provide the trial identifier (for example, the trial registration number), and be clearly identified as secondary publications. Secondary publications should be scientifiy justified based on their value in contributing to scientific knowledge or clinical practice. Authors preparing secondary publications and presentations should avoid redundancy (that is, duplication of previously published data) and unjustified splitting of study findings across several publications. Previous congress presentations of a study should be disclosed when a manuscript is submitted to a journal. Authorship of secondary publications and presentations may differ from that of primary publications and presentations from the same study. We recommend that 1 or more authors of the primary publication of a study contribute to any secondary publications and presentations, either as an author or contributor, to ensure appropriate understanding and interpretation of the orinal study and subsequent analyses. Congress guidelines should be followed for abstract submissions and presentations. Authors should disclose prior presentations at other congresses (if the abstract submission system allows) and include the trial registration number, if possible. The same authorship criteria used for journal publications (for example, as described by the ICMJE) should be used for congress presentations. A repeated presentation of the data to different congresses is permissible to reach different audiences, provided that the congress permits this "encore" presentation and copyrht requirements are respected. Encore presentations should usually have the same authorship as the orinal presentation. However, authorship of encore presentations at national or local meetings may differ slhtly (for example, to enable presentation in the appropriate language in situations where the congress does not allow nonauthor presenters), provided that all orinal authors agree. Review articles should be comprehensive, and the methods used for searching, selecting, and summarizing information should be clearly stated. For systematic reviews, the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines should be followed. Narrative literature reviews should have a clear scientific or clinical rationale (for example, educational need or literature gap) for publication. Discussions or recommendations founded principally on opinion rather than on a synthesis of the available evidence should be clearly identified as such. The sponsor's role, if any, should be acknowledged (for example, funding for medical writing or editorial support and review of the data for scientific or medical accuracy). Authors should follow established reporting standards for specific study types (for example, CONSORT [Consolidated Standards of Reporting Trials], STROBE [STrengthening the Reporting of OBservational studiesin Epidemiology], and PRISMA). These and other reporting guidelines are available on the EQUATOR Network ( Sharing and public posting of clinical trial data, including full study reports and individual patient-level data, have the potential to advance science, increase the efficiency of clinical research, and enhance transparency and trust in the process. However, publishing patient-level data may also raise concerns about confidentiality. Regulations, recommendations, and journal requirements in this area are evolving rapidly (17, 32–34). Some journals have introduced requirements to make orinal data, including patient-level data and redacted protocols, available in repositories or on request to qualified researchers (35, 36) or require protocols for review and public posting (37, 38). Other journals (including We recommend that, in addition to following applicable rules, legislation, and guidelines, sponsors grant access to patient-level data to qualified researchers on request. Supplied reports should be redacted to protect patient confidentiality. Methods of data analysis, presentation, and the definition of the study end point (which varies by local law) should be fully described and defined in all reports (including clinical trial registries) and publications. Authors are listed in order of lead and second author, based on their contributions, with subsequent authors listed in alphabetical order. All of the authors contributed to the outline, first and subsequent drafts, and assessment and incorporation of the comments received during the review phase; further, they approved the final draft. Chris Graf shared details about the processes used for GPP2 at the initiation of the GPP3 project. All of the authors reviewed each draft critiy and met ICMJE criteria for authorship. Veitch was the subcommittee lead for sections 1.7, 2.3, 2.4, and 5.0. Wager had the idea for including a section on general principles, wrote the first draft, and was the subcommittee lead for that section; she participated as a member of the subcommittee for section 2.4 and edited the entire manuscript before and after the review stage for clarity and consistency. Woolley was the subcommittee lead for section 2.4 and the Future Directions paragraph. Yarker initiated the development of GPP3 along with Dr. Aya Tokaji (Mc Cann Complete Medical , MDS-CMG Japan, Tokyo, Japan); Chris Graf (Wiley Blackwell, Oxford, United Kingdom); and Mina Patel, Ph D (Biogen, Cambridge, Massachusetts), were members of the steering committee and contributed to discussions about some of the recommendations made in this document. Terms of Use The In the Clinic® slide sets are owned and copyrhted by the American College of Physicians (ACP). All others who contributed to this document, but who did not meet authorship criteria, are acknowledged. Battisti initiated the development of GPP3 (along with Dr. Moore tracked the communications with the additional solicited reviewers and was a subcommittee member for sections 2.4 and 2.5. Peñ participated as a subcommittee member for sections 2.6 and 5.0 and verified all references with Dr. Battisti and participated as a member of the subcommittees that developed sections 1.2, 2.4, and 3.0. Wager wrote much of the first version of GPP (on which GPP2 and GPP3 were based); further, Drs. All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. Yarker), was the chair of the steering committee, and oversaw the guideline development process, including the assembling, editing, and formatting of each complete draft. Baltzer was the subcommittee lead for sections 3.0 and 4.0 and a member of the subcommittees that developed portions of sections 1.2 through 1.8 and 2.0. Battisti wrote the first draft of the abstract, introduction, aims and scope, and methods and participated as a member of the subcommittees for section 2.3. Bridges was the subcommittee lead for section 2.0 and a member of the subcommittee that developed sections 1.1 and 1.3 through 1.8. Cairns was the subcommittee lead for section 2.5 and a member of the subcommittee that developed sections 2.1 through 2.3 and 2.6. Carswell was the subcommittee lead for section 2.3, wrote the first draft, and revised subsequent versions of that section. Citrome was the subcommittee lead for section 2.6, wrote the first draft and revised subsequent versions of that section, and was a member of the subcommittees that developed sections 1.2 and 2.1 through 2.3. Gurr was the subcommittee lead for section 1.2 and a member of the subcommittees that developed the sections 2.1, 2.2, 2.4, and 2.5. Sanes-Miller was a member of the subcommittees on sections 2.3 and 2.6 and contributed to these and other sections. Mooney was a contributor to sections 1.2, 1.3, and 5.0 and verified all references with Dr. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyrht notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyrht infringement. No external sponsors were involved in the preparation of this manuscript, and no external funding was used. KW is a co-author of GPP3 GPP3 - A welcome addition to publication guidelines We, the Global Alliance of Publication Professionals (GAPP; would like to congratulate both Battisti et al and Ann Intern Med on the e-publication of the GPP3 guidelines. Although the previous GPP guidelines (published in 20) and substantial efforts by medical journal editors, the pharmaceutical industry, and communication professionals have led to an improvement in publication ethics and transparency, questions persist about the publication of company-sponsored medical research. Lack of awareness and confusion can lead to unintended consequences, such as poor publication practices and, worse, delayed publication of research findings. Publication of the GPP3 guidelines in a widely disseminated, respected journal will help to clarify the complex areas surrounding authorship, data sharing and the role of professional medical writers. Indeed, by following these guidelines, there should be no accusation of ghost-writing directed at ‘properly acknowledged professional medical writers’. Clarification regarding the rare occasions when medical writers qualify for authorship, the approach for specific publication types and acknowledging the main reporting standards are also welcome. These important guidelines are relevant to the many professionals involved in the communication of company-sponsored medical research, who wish to publish their findings ethiy and efficiently. As GPP and GPP2 before, GPP3 will become an essential point of reference. Cheap research proposal writing site us - Cheap Research Proposal Writers Site best on presidential elections popular descriptive essay writing for.

<em>Professional</em> College Essay <em>Ghostwriting</em> Website Au, Buy Essay.
Localización gav-
Tilaa lehti – Pro Sail
<em>Professional</em> Thesis <em>Proposal</em> <em>Ghostwriting</em> <em>Sites</em> Gb - hrmin

Professional research proposal ghostwriting sites au:

Rating: 87 / 100

Overall: 91 Rates

Добавить комментарий

Ваш e-mail не будет опубликован. Обязательные поля помечены *